Purple Biotech (PPBT) Cash & Current Investments (2014 - 2026)

Purple Biotech (PPBT) has reported Cash & Current Investments for 13 consecutive years, with $6.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Current Investments fell 2.9% year-over-year to $6.4 million; the TTM figure through Mar 2026 stood at $6.4 million (down 2.9% YoY), while the FY2025 annual figure was $9.6 million, up 24.73% from the prior year.
• Cash & Current Investments fell to $6.4 million in Q1 2026 per PPBT's latest filing, from $9.6 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $39.5 million in Q1 2022 and bottomed at $5.6 million in Q2 2025.
• Historically, Cash & Current Investments has averaged $15.7 million across 5 years, with a median of $10.8 million in 2024.
• Annual changes were most pronounced in 2022 — Cash & Current Investments slumped 67.24% — and 2025, when it jumped 66.31%.
• Purple Biotech's Cash & Current Investments stood at $15.5 million in 2022, then dropped by 0.79% to $15.3 million in 2023, then tumbled by 49.96% to $7.7 million in 2024, then increased by 24.73% to $9.6 million in 2025, then plunged by 32.88% to $6.4 million in 2026.
• Business Quant data shows PPBT's Cash & Current Investments at $6.4 million in Q1 2026, $9.6 million in Q4 2025, and $10.5 million in Q3 2025.